Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder.
Expert Opin Emerg Drugs
; 29(3): 193-204, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38682267
ABSTRACT
INTRODUCTION:
Major depression is a common, disabling mental health condition associated with the highest disease burden for any neuropsychiatric disorder worldwide, according to the WHO. Due to the imperfect efficacy and tolerability profiles of existing treatments, investigational compounds in novel treatment classes are needed. Opioid-receptor antagonists are a potential new class of treatments currently under investigation. AREAS COVERED Major depressive disorder is first overviewed. Existing treatments, both their mechanisms of action and their place within the antidepressant space, are discussed herein. Then, the profile of Aticaprant and the wider context of kappa-opioid antagonism for depression are discussed in focus. EXPERT OPINION Early evidence indicates that Aticaprant may possess desirable pharmacodynamic and pharmacokinetic properties. A lack of convincing efficacy data at the time of writing precludes any definitive statement on its potential as an antidepressant.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores Opioides kappa
/
Transtorno Depressivo Maior
/
Antidepressivos
/
Antagonistas de Entorpecentes
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article